Payment overview · 2025
General Payments
$309.36
16 reported records · 7 companies
Healthcare provider profile · identity verified
Tri Minh Le, MD
Allopathic & Osteopathic Physicians|Family Medicine · COLDSPRING, TX · NPI 1205848033
Verified facts
What the public records show
CMS Open Payments records show Tri Minh Le, MD received $309.36 in general payments during 2025 across 16 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $71.84 | 23.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $67.72 | 21.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.09 | 18.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.46 | 15.7% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.06 | 7.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.87 | 6.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.32 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $309.36 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $71.84 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $67.72 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $67.72 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.09 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $48.46 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.46 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $20.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 154 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 131 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
154 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
131 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
154 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 419 | 163 |
| Lisinopril | Lisinopril | 406 | 129 |
| Atorvastatin Calcium | Atorvastatin Calcium | 378 | 126 |
| Azithromycin | Azithromycin | 375 | 244 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 351 | 59 |
| Gabapentin | Gabapentin | 335 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 327 | 108 |
| Metformin Hcl | Metformin Hcl | 320 | 105 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 301 | 126 |
| Fluticasone Propionate | Fluticasone Propionate | 284 | 142 |
| Levothyroxine Sodium | Levothyroxine Sodium | 259 | 74 |
| Cefdinir | Cefdinir | 252 | 166 |
| Pantoprazole Sodium | Pantoprazole Sodium | 232 | 74 |
| Furosemide | Furosemide | 231 | 76 |
| Omeprazole | Omeprazole | 223 | 64 |
| Trazodone Hcl | Trazodone Hcl | 213 | 68 |
| Potassium Chloride | Potassium Chloride | 180 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 55 |
| Eliquis | Apixaban | 154 | 29 |
| Buspirone Hcl | Buspirone Hcl | 149 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 146 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 142 | 47 |
| Carvedilol | Carvedilol | 135 | 39 |
| Losartan Potassium | Losartan Potassium | 135 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 131 | 46 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 131 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 130 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 48 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 111 | 44 |
| Methylprednisolone | Methylprednisolone | 110 | 81 |
| Ozempic | Semaglutide | 108 | 20 |
| Simvastatin | Simvastatin | 99 | 32 |
| Januvia | Sitagliptin Phosphate | 95 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 89 | 54 |
| Sertraline Hcl | Sertraline Hcl | 89 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 25 |
| Famotidine | Famotidine | 80 | 30 |
| Jardiance | Empagliflozin | 80 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 77 | 55 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 76 | 50 |
| Fenofibrate | Fenofibrate Nanocrystallized | 73 | 22 |
| Tramadol Hcl | Tramadol Hcl | 73 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 70 | 57 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 69 | 22 |
| Allopurinol | Allopurinol | 68 | 21 |
| Clonidine Hcl | Clonidine Hcl | 67 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 65 | 28 |
| Alprazolam | Alprazolam | 62 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 15 |
| Glipizide | Glipizide | 58 | 21 |
| Mounjaro | Tirzepatide | 58 | 12 |
| Doxepin Hcl | Doxepin Hcl | 57 | 29 |
| Propranolol Hcl | Propranolol Hcl | 57 | suppressed |
| Meloxicam | Meloxicam | 55 | 29 |
| Nifedipine Er | Nifedipine | 51 | 16 |
| Ibuprofen | Ibuprofen | 50 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 38 |
| Glipizide Er | Glipizide | 46 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 33 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | suppressed |
| Prednisone | Prednisone | 44 | 18 |
| Myrbetriq | Mirabegron | 43 | 15 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Baclofen | Baclofen | 37 | suppressed |
| Fluconazole | Fluconazole | 36 | 28 |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | 11 |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 31 | 22 |
| Naproxen | Naproxen | 31 | 20 |
| Pregabalin | Pregabalin | 31 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | 11 |
| Bupropion Xl | Bupropion Hcl | 28 | 11 |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Atenolol | Atenolol | 27 | 11 |
| Bumetanide | Bumetanide | 27 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Movantik | Naloxegol Oxalate | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 20 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 19 |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 23 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | 16 |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 18 |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 16 |
| Valacyclovir | Valacyclovir Hcl | 21 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 19 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 11 |
| Spironolactone | Spironolactone | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $309.36 · 16 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAPLYTA, COBENFY, ELIQUIS, KEVEYIS, NURTEC ODT, OTEZLA, REPATHA, TRELEGY ELLIPTA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error